VV

Vivoryon Therapeutics NVAMS Vivoryon Therapeutics Stock Report

Last reporting period 30 Jun, 2023

Updated 11 Nov, 2024

Last price

Market cap $B

0.064

Micro

Exchange

XAMS - Euronext Amsterdam

VVY.AS Stock Analysis

VV

Uncovered

Vivoryon Therapeutics NV is uncovered by Eyestock quantitative analysis.

Market cap $B

0.064

Dividend yield

Shares outstanding

24.105 B

Vivoryon Therapeutics NV is a biopharmaceutical company, which engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. The company is headquartered in Halle, Sachsen-Anhalt and currently employs 15 full-time employees. The company went IPO on 2014-10-27. The firm is developing a directed pipeline of product candidates with the project being a therapeutic approach for the treatment of AD. Its operations focus on the discovery and development of therapeutic programs, whereas operational research and development work is mainly outsourced to respective professional contract research organizations (CROs) or academic collaboration partners. Vivoryon strives to generate future revenues from licensing its product candidates to biopharmaceutical companies after development steps have been achieved or by commercializing products.

View Section: Eyestock Rating